| scholarly article | Q13442814 |
| P50 | author | Shuji Ogino | Q18055035 |
| Curtis Huttenhower | Q19397499 | ||
| Edward L. Giovannucci | Q20740896 | ||
| Levi Waldron | Q41044211 | ||
| Zhi Rong Qian | Q57252510 | ||
| Yujin Hoshida | Q86559026 | ||
| Charles S. Fuchs | Q88762246 | ||
| Aya Kuchiba | Q90598183 | ||
| Teppei Morikawa | Q90657039 | ||
| Reiko Nishihara | Q95974375 | ||
| Xiaoyun Liao | Q114321054 | ||
| Mai Yamauchi | Q114421478 | ||
| P2093 | author name string | Yu Imamura | |
| Andrew T Chan | |||
| P2860 | cites work | MethyLight: a high-throughput assay to measure DNA methylation | Q24515378 |
| CpG Island Methylation in Colorectal Cancer: Past, Present and Future | Q24597977 | ||
| Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field | Q24620628 | ||
| CpG island methylator phenotype in colorectal cancer | Q24672170 | ||
| Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. | Q27851408 | ||
| CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer | Q29614277 | ||
| Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample | Q33383866 | ||
| DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. | Q33517453 | ||
| Colorectal Cancer Epigenetics: Complex Simplicity | Q37827277 | ||
| Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location | Q37992642 | ||
| The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status | Q38417609 | ||
| Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases | Q43735744 | ||
| The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdr1a suppresses polyp formation in Apc(Min/+) mice | Q44478672 | ||
| Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles | Q46335149 | ||
| Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer | Q46578998 | ||
| Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. | Q54559325 | ||
| Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. | Q54583151 | ||
| Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. | Q54631097 | ||
| The Role of hMLH1 Methylation in the Development of Synchronous Sporadic Colorectal Carcinomas | Q56590904 | ||
| Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability | Q58277316 | ||
| Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression | Q58613225 | ||
| Aberrant expression of pRb and p16(INK4), alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma | Q80880949 | ||
| Colorectal anatomy in adults at computed tomography colonography: normal distribution and the effect of age, sex, and body mass index | Q84384388 | ||
| Three DNA methylation epigenotypes in human colorectal cancer | Q33520394 | ||
| Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells | Q33525767 | ||
| Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer | Q33526369 | ||
| Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features | Q33584274 | ||
| A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers | Q33808550 | ||
| Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). | Q33869180 | ||
| Microbes in gastrointestinal health and disease | Q33943525 | ||
| Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer | Q33954716 | ||
| Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers | Q34143733 | ||
| Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? | Q34190195 | ||
| Gene expression in fixed tissues and outcome in hepatocellular carcinoma. | Q34235518 | ||
| Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer | Q34358286 | ||
| Colorectal cancer molecular biology moves into clinical practice | Q34425013 | ||
| Are there two sides to colorectal cancer? | Q34822109 | ||
| Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer | Q34921255 | ||
| Cancer immunology--analysis of host and tumor factors for personalized medicine | Q35583180 | ||
| Genome-scale analysis of aberrant DNA methylation in colorectal cancer | Q35694387 | ||
| CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies | Q35760749 | ||
| Sensitive sequencing method for KRAS mutation detection by Pyrosequencing | Q35789986 | ||
| Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis | Q35790157 | ||
| CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations | Q35807863 | ||
| Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample | Q35855515 | ||
| Two colons-two cancers: paradigm shift and clinical implications | Q35964258 | ||
| Molecular classification and correlates in colorectal cancer | Q36329300 | ||
| Concordant DNA methylation in synchronous colorectal carcinomas. | Q36529752 | ||
| PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. | Q36661711 | ||
| Loss of Rb1 in the gastrointestinal tract of Apc1638N mice promotes tumors of the cecum and proximal colon. | Q36926836 | ||
| LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. | Q37070832 | ||
| A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer | Q37090752 | ||
| CpG island methylator phenotype (CIMP) in cancer: causes and implications | Q37159995 | ||
| CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer | Q37185561 | ||
| A comparison of colon and rectal somatic DNA alterations | Q37283757 | ||
| Role of the serrated pathway in colorectal cancer pathogenesis | Q37737403 | ||
| Innate immune mechanisms of colitis and colitis-associated colorectal cancer | Q37820065 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dichotomy | Q10361123 |
| colorectal cancer | Q188874 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 847-54 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Gut | Q5621669 |
| P1476 | title | Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum | |
| P478 | volume | 61 |
| Q37600941 | (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status |
| Q64235538 | A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update |
| Q36245897 | A Comprehensive Model of Colorectal Cancer by Risk Factor Status and Subsite Using Data From the Nurses' Health Study |
| Q52560123 | A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine. |
| Q36854546 | A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer |
| Q37003013 | A pilot study comparing protein expression in different segments of the normal colon and rectum and in normal colon versus adenoma in patients with Lynch syndrome |
| Q41686298 | A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites |
| Q36974863 | A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification |
| Q49691234 | ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. |
| Q35815658 | Adulthood Weight Change and Risk of Colorectal Cancer in the Nurses' Health Study and Health Professionals Follow-up Study |
| Q33611163 | Age-specific prevalence of serrated lesions and their subtypes by screening colonoscopy: a retrospective study |
| Q90208674 | An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer |
| Q33732199 | Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review |
| Q36342900 | Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance) |
| Q38385410 | Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial |
| Q37179522 | Anatomic subsite of primary colorectal cancer and subsequent risk and distribution of second cancers |
| Q55379897 | Ancient Thali Diet: Gut Microbiota, Immunity, and Health. |
| Q36345775 | Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. |
| Q37626475 | Aspirin and colorectal cancer: back to the future |
| Q38036541 | Aspirin as adjuvant therapy for colorectal cancer—reinterpreting paradigms |
| Q47171553 | Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells |
| Q37094281 | Aspirin use and risk of colorectal cancer according to BRAF mutation status |
| Q28277824 | Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival |
| Q43870368 | Aspirin,PIK3CAMutation, and Colorectal-Cancer Survival |
| Q36267137 | Assessing the potential value of long interspersed element-1 hypomethylation in colorectal cancer: evidence from retrospective studies |
| Q37376477 | Assessment of epigenetic alterations in early colorectal lesions containing BRAF mutations. |
| Q60935427 | Association between Cardiovascular Risk and Diabetes with Colorectal Neoplasia: A Site-Specific Analysis |
| Q39921888 | Association between adenoma location and risk of recurrence |
| Q48010330 | Association between clinicopathological characteristics and RAS mutation in colorectal cancer |
| Q33739940 | Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation |
| Q92126721 | Association between local immune cell infiltration, mismatch repair status and systemic inflammatory response in colorectal cancer |
| Q34607305 | Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors |
| Q41372623 | Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway |
| Q35251591 | Association of Nonsteroidal Anti-Inflammatory Drugs with Colorectal Cancer by Subgroups in the VITamins and Lifestyle (VITAL) Study |
| Q33855053 | Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). |
| Q36306276 | BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics |
| Q41056167 | BRAF mutation-specific promoter methylation of FOX genes in colorectal cancer |
| Q33808553 | Biomarker correlation network in colorectal carcinoma by tumor anatomic location |
| Q95407965 | Bridging Behavior and Biology to Reduce Socioeconomic Disparities in Colorectal Cancer Risk |
| Q38690051 | British Society of Gastroenterology position statement on serrated polyps in the colon and rectum |
| Q34805465 | Calcium-sensing receptor silencing in colorectal cancer is associated with promoter hypermethylation and loss of acetylation on histone 3. |
| Q37299578 | Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies |
| Q36218282 | Characteristics of Differently Located Colorectal Cancers Support Proximal and Distal Classification: A Population-Based Study of 57,847 Patients |
| Q90050818 | Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials |
| Q41082092 | Circulating APRIL levels are correlated with advanced disease and prognosis in rectal cancer patients |
| Q49586760 | Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes |
| Q102059072 | Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab |
| Q37708040 | Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer |
| Q64102890 | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy |
| Q64123101 | Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis |
| Q92514791 | Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer |
| Q40992306 | Clinicopathological characteristics of young patients with sporadic colorectal cancer |
| Q94527907 | Clinicopathological differences and correlations between right and left colon cancer |
| Q64120101 | Colon Cancer Sidedness, Presentation, and Survival at Different Stages |
| Q37002257 | Colon and rectal cancer survival by tumor location and microsatellite instability: the Colon Cancer Family Registry. |
| Q89727321 | Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants |
| Q88780422 | Colorectal Cancer: Why Does Side Matter? |
| Q89218269 | Colorectal cancer |
| Q35935945 | Colorectal cancer: a tale of two sides or a continuum? |
| Q55411157 | Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. |
| Q28284149 | Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features |
| Q54297781 | Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors. |
| Q36195885 | Commentary: Lifestyle factors and colorectal cancer microsatellite instability--molecular pathological epidemiology science, based on unique tumour principle |
| Q46185591 | Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. |
| Q92709364 | Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients |
| Q38843102 | Comprehensive site-specific whole genome profiling of stromal and epithelial colonic gene signatures in human sigmoid colon and rectal tissue |
| Q34598203 | Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations |
| Q58699461 | Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis |
| Q91936129 | Crypt- and Mucosa-Associated Core Microbiotas in Humans and Their Alteration in Colon Cancer Patients |
| Q47562422 | DNA hypermethylation as a predictor of extramural vascular invasion (EMVI) in rectal cancer. |
| Q51022759 | Deficiency of caveolin-1 in Apcmin/+ mice promotes colorectal tumorigenesis |
| Q53141713 | Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp genetics |
| Q61197458 | Detection and differential diagnosis of colon cancer by a cumulative analysis of promoter methylation |
| Q36279671 | Detection of Polyps After Resection of Colorectal Cancer |
| Q36571334 | Diabetes Mellitus and Site-specific Colorectal Cancer Risk in Korea: A Case-control Study |
| Q93143158 | Diet and colorectal cancer in UK Biobank: a prospective study |
| Q38935141 | Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes. |
| Q37629413 | Dietary patterns during high school and risk of colorectal adenoma in a cohort of middle-aged women |
| Q36819611 | Dietary polyphenols and colorectal cancer risk: The Fukuoka colorectal cancer study |
| Q38401874 | Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk study |
| Q52558651 | Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum. |
| Q52586738 | Differences between carcinoma of the cecum and ascending colon: Evidence based on clinical and embryological data |
| Q57166687 | Different Anatomical Subsites of Colon Cancer and Mortality: A Population-Based Study |
| Q26865322 | Different treatment strategies and molecular features between right-sided and left-sided colon cancers |
| Q40428222 | Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location |
| Q27011884 | Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology |
| Q35773077 | Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. |
| Q34004693 | Distinct molecular features of different macroscopic subtypes of colorectal neoplasms |
| Q37432567 | Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon |
| Q47124374 | Does primary tumor location impact the prognosis of colorectal liver metastases patients after microwave ablation? - Lessons from 10 years' experience |
| Q26995653 | EMAST is a Form of Microsatellite Instability That is Initiated by Inflammation and Modulates Colorectal Cancer Progression |
| Q35546497 | Early life body fatness and risk of colorectal cancer in u.s. Women and men-results from two large cohort studies |
| Q27012841 | Early-onset colorectal cancer: a separate subset of colorectal cancer |
| Q55125985 | Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. |
| Q47236614 | Enterotypes in the landscape of gut microbial community composition. |
| Q34487177 | Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers |
| Q59334871 | Establishment, functional and genetic characterization of three novel patient-derived rectal cancer cell lines |
| Q35037282 | Estrogen receptors and their implications in colorectal carcinogenesis |
| Q26852716 | Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression |
| Q41817645 | Expression changes of cell-cell adhesion-related genes in colorectal tumors. |
| Q51134123 | Extent of field change in colorectal cancers with BRAF mutation |
| Q52666988 | FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis |
| Q41295657 | Factors associated with reclassification of hyperplastic polyps after pathological reassessment from screening and surveillance colonoscopies |
| Q53639784 | Familial colorectal cancer risk by subsite of primary cancer: a population-based study in Utah |
| Q90450020 | First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials |
| Q35956384 | Fusobacterium nucleatum and T Cells in Colorectal Carcinoma |
| Q39217446 | Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location |
| Q40603067 | Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis |
| Q90705442 | Gallbladder Polyps Are Associated with Proximal Colon Polyps |
| Q34500078 | Genome-Scale Discovery of DNA-Methylation Biomarkers for Blood-Based Detection of Colorectal Cancer |
| Q37027423 | Genome-wide association study identifies possible genetic risk factors for colorectal adenomas |
| Q39345973 | Genome-wide screening for understanding the role of DNA methylation in colorectal cancer |
| Q37274510 | Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas |
| Q48303532 | Genotyping of KRAS Mutational Status by the In-Check Lab-on-Chip Platform. |
| Q34373421 | Global mutational profiling of formalin-fixed human colon cancers from a pathology archive |
| Q35562401 | Gut microbiota. Microbiota organization--a key to understanding CRC development. |
| Q60297370 | Heterogeneity of Colorectal Cancer Risk Factors by Anatomical Subsite in 10 European Countries: A Multinational Cohort Study. |
| Q47943394 | High prevalence of sessile serrated adenomas in contemporary outpatient colonoscopy practice |
| Q45797683 | Histone Methyltransferase SETDB1 Promotes the Progression of Colorectal Cancer by Inhibiting the Expression of TP53. |
| Q36238965 | How many diseases are colorectal cancer? |
| Q89804300 | Identification of risk factors associated with stage III disease in non-metastatic colon cancer: Results from a prospective national cohort study |
| Q58596327 | Impact of Global DNA Methylation in Treatment Outcome of Colorectal Cancer Patients |
| Q64059301 | Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series |
| Q85505714 | Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients |
| Q35130874 | Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers |
| Q62494554 | Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology |
| Q53601791 | Integration of pharmacology, molecular pathology, and population data science to support precision gastrointestinal oncology. |
| Q50043586 | Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine |
| Q24289208 | Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science |
| Q46353757 | Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma |
| Q47550821 | Is the Location of the Tumor Another Prognostic Factor for Patients With Colon Cancer? |
| Q36213070 | Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype |
| Q33693309 | KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). |
| Q36889656 | KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers |
| Q35547217 | LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy |
| Q36414307 | LINE-1 hypomethylation in normal colon mucosa is associated with poor survival in Chinese patients with sporadic colon cancer. |
| Q34487770 | Laser microdissection and two-dimensional difference gel electrophoresis reveal proteomic intra-tumor heterogeneity in colorectal cancer |
| Q92638543 | Laterality: Immunological Differences Between Right-Sided and Left-Sided Colon Cancer |
| Q34038277 | Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial |
| Q38194035 | Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application |
| Q35045711 | Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients |
| Q38667176 | Management of resectable colorectal lung metastases |
| Q35474059 | Marine ω-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability |
| Q89171911 | Meta-analysis of the prognostic value of CpG island methylator phenotype in rectal cancer |
| Q54220105 | Methylation epigenotypes and genetic features in colorectal laterally spreading tumors |
| Q44981365 | MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions. |
| Q90216526 | Microarray‑based analysis of COL11A1 and TWIST1 as important differentially‑expressed pathogenic genes between left and right‑sided colon cancer |
| Q35120938 | Microbes, microbiota, and colon cancer |
| Q37075412 | Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication |
| Q40975682 | Mismatch repair deficiency as a prognostic factor in mucinous colorectal cancer |
| Q37708015 | Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. |
| Q37394567 | Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer |
| Q41539678 | Molecular markers and pathway analysis of colorectal carcinoma in the Middle East. |
| Q24289344 | Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease |
| Q30244608 | Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. |
| Q44891666 | Molecular pathological findings of Merkel cell polyomavirus in lung cancer: a possible etiopathogenetic link? |
| Q26785725 | Molecular phenotypes of colorectal cancer and potential clinical applications |
| Q35447606 | Molecular subtypes in stage II-III colon cancer defined by genomic instability: early recurrence-risk associated with a high copy-number variation and loss of RUNX3 and CDKN2A. |
| Q35124378 | Multiple sporadic colorectal cancers display a unique methylation phenotype |
| Q48072505 | Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis |
| Q36936956 | Mutation profiles of synchronous colorectal cancers from a patient with Lynch syndrome suggest distinct oncogenic pathways |
| Q34457478 | Nutrients, foods, and colorectal cancer prevention |
| Q92875232 | Oral Bacteria and Intestinal Dysbiosis in Colorectal Cancer |
| Q40235695 | PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer. |
| Q34778710 | PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival |
| Q49996562 | PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients |
| Q42356938 | PIK3CA mutation and colorectal cancer precision medicine. |
| Q36050773 | PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study |
| Q35583813 | Pan-cancer stratification of solid human epithelial tumors and cancer cell lines reveals commonalities and tissue-specific features of the CpG island methylator phenotype |
| Q36201032 | Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. |
| Q64264728 | Periodontitis is associated with an increased risk for proximal colorectal neoplasms |
| Q38363276 | Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies |
| Q37172368 | Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. |
| Q91646491 | Physical Activity and Colorectal Cancer Prognosis According to Tumor-Infiltrating T Cells |
| Q36926941 | Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer |
| Q34485223 | Podocalyxin is a marker of poor prognosis in colorectal cancer |
| Q89445761 | Post-colonoscopy colorectal cancer: the key role of molecular pathological epidemiology |
| Q36295062 | Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers. |
| Q34502713 | Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. |
| Q37360360 | Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. |
| Q35729861 | Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803 |
| Q41757471 | Predictors of long-term survival in patients with stage IV colorectal cancer with multi-organ metastases: a single-center retrospective analysis |
| Q49311582 | Preoperative anemia in colorectal cancer: relationships with tumor characteristics, systemic inflammation, and survival |
| Q37675952 | Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients |
| Q94526860 | Primary tumor location and survival in colorectal cancer: A retrospective cohort study |
| Q36047405 | Primary tumor location as a prognostic factor in metastatic colorectal cancer. |
| Q47163641 | Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer |
| Q36028658 | Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study |
| Q92440787 | Primary tumour location affects survival after resection of colorectal liver metastases: A two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score |
| Q34475686 | Proceedings of the second international molecular pathological epidemiology (MPE) meeting |
| Q40243706 | Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. |
| Q64114518 | Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial |
| Q90953436 | Prognostic effect of sidedness in early stage versus advanced colon cancer |
| Q37111201 | Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location |
| Q30248900 | Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis |
| Q35137525 | Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma |
| Q59337413 | Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer |
| Q47121254 | Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer |
| Q33812820 | Progressive proximal-to-distal reduction in expression of the tight junction complex in colonic epithelium of virally-suppressed HIV+ individuals. |
| Q36675320 | Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with β-catenin (CTNNB1) status. |
| Q36535688 | Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level |
| Q50111084 | Prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2), a complex target for colorectal cancer prevention and therapy |
| Q42873640 | RE: Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer |
| Q57821644 | Recent advances in understanding colorectal cancer |
| Q64043490 | Redefining synchronous colorectal cancers based on tumor clonality |
| Q36968401 | Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine |
| Q35879988 | Review of the development of DNA methylation as a marker of response to neoadjuvant therapy and outcomes in rectal cancer. |
| Q45365003 | Right- and left-sided colorectal cancers respond differently to traditional Chinese medicine |
| Q64927739 | Right- and left-sided stage III colon cancers present different prognostic outcomes of oxaliplatin-based adjuvant chemotherapy after curative resection. |
| Q102220443 | Rising incidence of early-onset colorectal cancer - a call to action |
| Q66475538 | Rotating night shift work and colorectal cancer risk in the nurses' health studies |
| Q34458644 | SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features |
| Q38722180 | Segmental distribution of some common molecular markers for colorectal cancer (CRC): influencing factors and potential implications |
| Q26827208 | Serrated lesions of the colorectum: review and recommendations from an expert panel |
| Q38473801 | Serrated neoplasia-role in colorectal carcinogenesis and clinical implications |
| Q39414117 | Shaping functional gut microbiota using dietary bioactives to reduce colon cancer risk |
| Q53164323 | Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies. |
| Q26795609 | Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance |
| Q86266290 | Site-specific colorectal cancer; how is it different? |
| Q57476251 | Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells |
| Q36108299 | Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer |
| Q37062872 | Sox9 induction, ectopic Paneth cells, and mitotic spindle axis defects in mouse colon adenomatous epithelium arising from conditional biallelic Apc inactivation |
| Q35124107 | Spatial modeling of colonic lesions with geographic information systems |
| Q39139086 | Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer |
| Q36068286 | Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy |
| Q61865595 | Subsets of microsatellite-unstable colorectal cancers exhibit discordance between the CpG island methylator phenotype and MLH1 methylation status |
| Q57088795 | Survival After Resection of Colorectal Cancer Based on Anatomical Segment of Involvement |
| Q64235690 | Survival Rate of Colorectal Cancer in Iran: A Systematic Review and Meta-Analysis |
| Q89097041 | TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas |
| Q36646911 | Targeted therapies in colorectal cancer—an integrative view by PPPM |
| Q59793052 | The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients |
| Q59796444 | The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome |
| Q36510909 | The Critical Role of Dysregulated FOXM1–PLAUR Signaling in Human Colon Cancer Progression and Metastasis |
| Q26745580 | The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment |
| Q48197461 | The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS. |
| Q42359699 | The clinical impact of tumour-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study |
| Q34450525 | The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer |
| Q26827391 | The gastrointestinal tumor microenvironment |
| Q47418712 | The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study |
| Q97525775 | The influence of mitochondrial-directed regulation of Wnt signaling on tumorigenesis |
| Q57602278 | The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer |
| Q33768220 | The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. |
| Q45722578 | The right colon--a real challenge for the endoscopist |
| Q46266500 | The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. |
| Q37130603 | The role of personalized medicine in metastatic colorectal cancer: an evolving landscape |
| Q40421012 | The serrated neoplasia pathway of colorectal tumors: Identification of MUC5AC hypomethylation as an early marker of polyps with malignant potential |
| Q51737468 | The significance of microsatellite instability in colorectal cancer after controlling for clinicopathological factors |
| Q26827212 | Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF |
| Q37534159 | Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. |
| Q37688202 | Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival |
| Q34169734 | Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis |
| Q57059651 | Tumor sidedness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer |
| Q97538994 | Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer |
| Q91710496 | Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials |
| Q37708920 | Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis. |
| Q38634544 | Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes |
| Q91887316 | Vitamin D differentially regulates colon stem cells in patient-derived normal and tumor organoids |
| Q42314685 | What roles do colon stem cells and gap junctions play in the left and right location of origin of colorectal cancers? |
| Q28109367 | Whole-genome methylation analysis of benign and malignant colorectal tumours |
| Q89797400 | Yogurt consumption and colorectal polyps |
| Q58122181 | and Colorectal Cancer |
Search more.